Abstract
Background Severe malaria and invasive non-typhoidal Salmonella (NTS) are life-threatening infections that often co-exist in African children. The iron-regulatory hormone hepcidin is highly upregulated during malaria and controls the availability of iron, a critical nutrient for bacterial growth, within the Salmonella-containing vacuole.
Methods We first investigated the relationship between Plasmodium falciparum malaria and NTS bacteremia in all pediatric admissions aged ≤5 years between August 1998 and October 2019 (n=75,015). We then assayed hepcidin and measures of iron status in five groups: (1) children with concomitant severe malaria anemia (SMA) and NTS (SMA+NTS, n=16); and in matched children with (2) SMA alone (n=33); (3) NTS alone (n=33); (4) cerebral malaria (CM, n=34); and (5) community-based children.
Results In hospitalized children SMA, but not other malaria phenotypes, was associated with an increased risk of NTS (adjusted OR 2.88 [95% CI 1.97, 4.23]; P<0.0001). Risk of NTS increased by 30% with each 1g/dl decrease in hemoglobin concentrations. In hospitalized children median hepcidin levels were lower in the SMA+NTS (9.3 ng/mL [interquartile range 4.7, 49.8]) and SMA (31.1 ng/mL [5.5, 61.2]) groups, compared to levels in those with CM (90.7 ng/mL [38.7, 176.1]) or NTS (105.8 ng/mL [17.3, 233.3]), despite similar ferritin and CRP levels. Soluble transferrin receptor levels were lower in the CM group compared to the other hospitalized groups.
Conclusion SMA was associated with increased risk of NTS and with reduced hepcidin levels. We hypothesized that reduced hepcidin might allow increased movement of iron into the Salmonella-containing vacuole favoring bacterial growth.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Wellcome (grant numbers 110255 to SHA, 212600 to KMA, 202800 to TNW, and a core award to the KEMRI-Wellcome Trust Research Programme [203077]). KMA and JMM were supported by the DELTAS Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from Wellcome [107769] and the UK government.
For the purpose of Open Access, the author has applied a CC-BY public copyright licence to any author accepted manuscript version arising from this submission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Scientific Ethics Review Unit of the Kenya Medical Research Institute
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0)
